Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03215511 · ClinicalTrials.gov registry record · Phase 1
A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 81
- Enrollment target
NCT03215511 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 81 participants.
The verdict
NCT03215511, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 81 participants
- Enrollment target
Study Summary
This research study is done to test the safety of the new drug selitrectinib in children and adults with cancer having a change in a particular gene (NTRK1, NTRK2 or NTRK3). The drug may treat cancer by interfering with the effect of the NTRK genes on cancer growth. The study also investigates how the drug is absorbed and processed in the human body, and how well and for how long the cancer responds to the drug. This is the first study to test selitrectinib in humans with cancer, for whom no other effective therapy exists.
Interventions
- DRUG Selitrectinib (BAY2731954)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2017-07-03 |
| Est. Completion | 2023-01-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03215511
The ClinicalTrials.gov registry entry for NCT03215511 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Selitrectinib (BAY2731954) is the first listed.
NCT03215511 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03215511 about?
NCT03215511 is a clinical study titled "A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer". This research study is done to test the safety of the new drug selitrectinib in children and adults with cancer having a change in a particular gene (NTRK1, NTRK2 or NTRK3). The drug may treat cancer by interfering with the effect of the NTRK genes on cancer growth. The study also investigates how t...
What is the current status of trial NCT03215511?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 81 participants. The study started on 2017-07-03. Estimated completion is 2023-01-30.
What interventions are being tested in trial NCT03215511?
The interventions under investigation include: Selitrectinib (BAY2731954) (DRUG).
Who is sponsoring clinical trial NCT03215511?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.